MEZZION PHARMA CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36,800 KRW | +2.22% |
|
-1.87% | -5.64% |
| Sales 2022 | 30.73B 22.28M | Sales 2023 | 31.72B 23M | Capitalization | 1,154B 837M |
|---|---|---|---|---|---|
| Net income 2022 | -36.3B -26.32M | Net income 2023 | -12.73B -9.23M | EV / Sales 2022 | 10.4 x |
| Net cash position 2022 | 28.69B 20.8M | Net cash position 2023 | 57.75B 41.87M | EV / Sales 2023 | 34.6 x |
| P/E ratio 2022 |
-9.57
x | P/E ratio 2023 |
-86.5
x | Employees | 45 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.39% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.22% | ||
| 1 week | -1.87% | ||
| Current month | -6.95% | ||
| 1 month | -14.12% | ||
| 3 months | -0.54% | ||
| 6 months | +5.90% | ||
| Current year | -5.64% |
1 week
35 500.00
37 850.00
1 month
35 500.0044 700.00
Current year
33 300.0050 200.00
1 year
19 550.0054 100.00
3 years
12 250.0076 566.67
5 years
12 250.0085 866.67
10 years
5 300.0085 866.67
| Managers | Title | Age | Since |
|---|---|---|---|
Dong-Hyun Park
FOU | Founder | 67 | 02-09-24 |
James L. Yeager
CTO | Chief Tech/Sci/R&D Officer | 77 | 04-12-31 |
Bill Breitenbach
PRN | Corporate Officer/Principal | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mitchell Steiner
BRD | Director/Board Member | 63 | - |
Dong-Hyun Park
FOU | Founder | 67 | 02-09-24 |
James L. Yeager
CTO | Chief Tech/Sci/R&D Officer | 77 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 34 M€ | +1.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 36,800 | +2.22% | 85,709 |
| 24-04-19 | 36,000 | -1.77% | 133,693 |
| 24-04-18 | 36,650 | +0.41% | 73,251 |
| 24-04-17 | 36,500 | -1.88% | 106,385 |
| 24-04-16 | 37,200 | -0.80% | 95,850 |
End-of-day quote Korea S.E., April 21, 2024
More quotes
Mezzion Pharma Co., Ltd. is a Korea-based company engaged in the pharmaceutical business. The Company focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The Company has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -5.64% | 793M | |
| +2.81% | 68.35B | |
| -16.14% | 4.78B | |
| +4.07% | 3.87B | |
| +19.02% | 3.73B | |
| +25.67% | 2.52B | |
| -27.48% | 2.27B | |
| -25.70% | 2.21B | |
| +7.46% | 1.95B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- A140410 Stock
